Abstract
KRAS is the most common oncogenic driver in NSCLC. Researchers previously reported that only KRAS mutation and KRAS co-mutated with STK11 define distinct subgroups of NSCLC, which response differently to immune checkpoint inhibitors (ICI). Herein, by means of evaluating the tumor immune microenvironment (TME) and some biomarkers, to explore the mechanism of different efficacy of ICI showed in these subgroup of Chinese NSCLC patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
